Federal Cannabis Reform Has “The Votes,” Top Democrat Says (Newsletter: April 22, 2026)
Federal cannabis reform would fundamentally alter the clinical landscape by removing barriers to research, standardizing product testing, and potentially enabling insurance coverage for medical cannabis. This would allow clinicians to practice evidence-based cannabis medicine with the same regulatory framework as other therapeutics.
A senior Democratic leader indicates sufficient congressional support exists for federal cannabis reform legislation. Current federal prohibition creates significant clinical challenges including limited research opportunities, inconsistent state-level regulations, and patient access barriers through insurance exclusions. Federal reform would likely enable DEA rescheduling, FDA oversight of medical products, and potential integration into standard healthcare delivery systems.
“After years of state-by-state patchwork, federal reform would finally let us practice cannabis medicine like real medicine — with proper research, consistent products, and insurance coverage for patients who need it most.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
